Document is current
Any future updates will be listed below
-
Authors
Ragozzino, Silvio https://orcid.org/0000-0002-8100-2096
Mueller, Nicolas J. https://orcid.org/0000-0002-1059-3191
Neofytos, Dionysios https://orcid.org/0000-0001-6970-2869
Passweg, Jakob https://orcid.org/0000-0001-7092-3351
Müller, Antonia
Medinger, Michael https://orcid.org/0000-0003-0427-7747
Van Delden, Christian
Masouridi-Levrat, Stavroula https://orcid.org/0000-0001-7502-5454
Chalandon, Yves https://orcid.org/0000-0001-9341-8104
Tschudin-Sutter, Sarah
Khanna, Nina https://orcid.org/0000-0002-2642-419X
,
Van Delden, Christian
- License Information
-
More Information
Article History
Received: 12 September 2023
Revised: 7 November 2023
Accepted: 16 November 2023
First Online: 30 November 2023
Competing interests
: NJM received consulting fees from MSD, Pfizer, travel grant from Biotest, Pfizer. DN received research support from MSD and Pfizer and consulting fees from Roche Diagnostics, MSD, Pfizer, Basilea, and Gilead. NJM received consulting fees from MSD, Pfizer, travel grant from Biotest, Pfizer. YC has received honoraria for participation in symposia and advisory boards from MSD, Novartis, Incyte, BMS, Pfizer, Abbvie, Roche, Jazz, Gilead, Amgen, Astra-Zeneca, Servier; Travel support from MSD, Roche, Gilead, Amgen, Incyte, Abbvie, Janssen, Astra-Zeneca, Jazz, Sanofi, all via the institution. NK received research grants from MSD and Debiopharm, consulting fees from MSD, Pfizer, Basilea, and Gilead, and speaker honoraria from Pfizer and MSD. All other authors have no potential conflicts of interest.
